SUNNYVALE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2022 and filed its quarterly report on Form 10-Q for the three and nine months ended […]
Financial
Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update
NDA for Sotagliflozin Remains on Track for May 2023 PDUFA Date Following Mid-Cycle Review Meeting Final Data from Successful RELIEF-DPN-1 Study of LX9211 in Painful Diabetic Neuropathy to Be Presented at 16th Annual Pain Therapeutics Summit Next Week Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, Nov. […]
Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update
– Phase 3 RAPID trial of etripamil in patients with PSVT achieved primary efficacy endpoint; safety and tolerability data from repeat dose administration consistent with prior studies utilizing single-dose administration of etripamil – Analyses from etripamil Phase 3 PSVT studies featured during Late-Breaking session at AHA Scientific Sessions 2022 demonstrated significant reductions […]
Silence Therapeutics Reports Third Quarter 2022 Results
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the third quarter ended September 30, 2022 and reviewed recent business highlights. “Silence’s third quarter was […]
Applied Therapeutics Reports Third Quarter 2022 Financial Results
NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2022. “In […]
LumiraDx Reports Third Quarter 2022 Results
Progress on Near-Term Growth Opportunities and Cost Savings LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) — LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced operational and financial results for the third quarter ended September 30, 2022. Q3 2022 revenue of $42.2 million compared to Q2 […]
Silk Road Medical Reports Third Quarter 2022 Financial Results
SUNNYVALE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended September 30, 2022. “Our performance in the third quarter reflects broad-based U.S. TCAR strength […]
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments potentially due from Amgen from the 2016 out licensing agreement NEW YORK and PASADENA, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) — Royalty […]
SVS Foundation Adds DEI Pillar
Contact: Beth Bales Senior Communications Manager, SVS (312) 334-2316 ROSEMONT, ILL. (Nov. 9, 2022) – The Society for Vascular Surgery (SVS) Foundation has been guided by the three long-term pillars of research and innovation, community vascular care and patient education, and disease prevention. Recently, the Foundation added a fourth pillar […]
Shockwave Medical Reports Third Quarter 2022 Financial Results
SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2022. Recent Highlights Recognized revenue of $131.3 million […]
Recent
Nyra Medical Receives Prestigious Jon DeHaan Foundation Award for Innovation in Cardiology at EuroPCR 2026
AHN’s Allegheny General Hospital Unveils New, State-of-the-Art Cardiac Cath and Electrophysiology Labs, following Completion of $19 Million Renovation Project
egnite Expands Medical Advisory Board with Three Nationally Recognized Cardiovascular Specialists
Popular
- No commented posts yet